Combination Muscle Relaxant + NSAID Therapy in PI Cases

James Wong — Founder & CEO, LienScripts | March 26, 2026 | 8 min read

Dual therapy combining a muscle relaxant with an NSAID addresses both spasm and inflammation simultaneously. Learn why this prescribing pattern documents injury complexity and strengthens settlement demands.

Combination Muscle Relaxant + NSAID Therapy in PI Cases

Combination therapy pairing a muscle relaxant with a nonsteroidal anti-inflammatory drug (NSAID) is a standard, evidence-based approach to managing musculoskeletal injuries from motor vehicle accidents and other trauma. The dual-agent prescribing pattern documents that the treating physician identified two distinct pathological processes — muscle spasm and inflammatory tissue damage — requiring separate pharmacological interventions, which directly strengthens the case narrative for settlement negotiations.

• Muscle relaxants (cyclobenzaprine, tizanidine, baclofen) target involuntary muscle spasm through central nervous system mechanisms
• NSAIDs (meloxicam, naproxen, diclofenac, celecoxib) target prostaglandin-mediated inflammation and pain at the tissue level
• Dual prescribing documents two concurrent injury mechanisms that a single medication cannot address
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that highlights combination therapy rationale with clinical annotations
• FDA guidelines support combination use, and PubMed evidence confirms superior outcomes versus monotherapy (PMID: 27557747)

Why Combination Therapy Matters for Case Value

When a physician prescribes both a muscle relaxant and an NSAID, they are making a clinical determination that the patient has two separate pathological conditions requiring independent treatment. According to James Wong, PharmD, founder of LienScripts, "Combination therapy is not overtreatment — it is a physician documenting that the injury created both a spasm problem and an inflammation problem, and that neither condition alone accounts for the patient's symptoms."

This distinction matters at settlement because defense counsel frequently argues that a single medication should suffice. The medical rationale for combination therapy directly refutes this position.

[!KEY] Dual muscle relaxant plus NSAID prescribing is not polypharmacy or overtreatment — it documents two distinct injury mechanisms (spasm and inflammation) requiring two pharmacologically different interventions, creating objective evidence of injury complexity that strengthens the demand.

The Clinical Rationale: Two Problems, Two Solutions

Muscle Spasm Pathway

After a traumatic injury, damaged muscles enter a protective spasm cycle. The muscle contracts involuntarily, reducing blood flow to the injured area, which increases pain, which triggers more spasm. Muscle relaxants break this cycle:

• Cyclobenzaprine reduces motor neuron activity at the brainstem level
• Tizanidine inhibits excitatory spinal motor neurons via alpha-2 receptors
• Baclofen restores GABA-B inhibitory signaling at the spinal cord

Inflammatory Pain Pathway

Simultaneously, damaged tissues release prostaglandins and other inflammatory mediators that cause swelling, sensitize pain receptors, and impair healing. NSAIDs block the cyclooxygenase (COX) enzymes responsible for prostaglandin production:

• Meloxicam preferentially inhibits COX-2 with once-daily dosing
• Naproxen provides broad COX-1/COX-2 inhibition with long duration
• Diclofenac offers potent anti-inflammatory effect with topical options
• Celecoxib selectively inhibits COX-2 with reduced GI risk

Neither class of medication can address both pathological processes. A muscle relaxant does not reduce tissue inflammation, and an NSAID does not relieve centrally-mediated spasm.

[!TIP] When reviewing pharmacy records, note whether the muscle relaxant and NSAID were prescribed on the same date or sequentially. Same-date prescribing indicates the physician identified both conditions at the initial evaluation. Sequential addition suggests the injury proved more complex than initially assessed — both patterns support the demand narrative.

Evidence Supporting Combination Therapy

A systematic review published in the Journal of Back and Musculoskeletal Rehabilitation found that combination therapy with a muscle relaxant and NSAID produced greater pain relief and functional improvement than either agent alone for acute musculoskeletal conditions (PubMed PMID: 27557747). The FDA labeling for cyclobenzaprine specifically describes its use "as an adjunct to rest and physical therapy" alongside analgesic medications.

The American College of Physicians recommends NSAIDs as first-line pharmacotherapy for acute low back pain, with muscle relaxants as an appropriate adjunct when spasm is present (Ann Intern Med. 2017;166(7):514-530).

Common Combination Patterns and What They Signal

Cyclobenzaprine + Meloxicam

The most common combination for acute whiplash and soft-tissue injuries. This pairing signals a standard musculoskeletal injury with both spasm and inflammation components. The physician has selected a moderate-potency muscle relaxant with a well-tolerated NSAID.

Tizanidine + Celecoxib

A more targeted combination suggesting the physician identified spinal-level spasticity (tizanidine) and chose a COX-2 selective NSAID to reduce GI risk during extended treatment. This combination signals greater injury severity and an anticipated longer treatment course.

Baclofen + Diclofenac (Topical or Oral)

An advanced combination indicating refractory spasm requiring GABA-B agonism alongside localized or systemic anti-inflammatory therapy. This pairing appears in more severe cases and carries significant documentation weight.

[!KEY] The specific combination chosen by the prescriber is itself evidence — a tizanidine plus celecoxib regimen signals greater severity and anticipated chronicity than cyclobenzaprine plus over-the-counter ibuprofen, and the MERIT report from LienScripts annotates these distinctions.

Documenting Combination Therapy in Demand Packages

The LienScripts platform tracks every medication dispensed on lien with dates, prescriber, and clinical context. For combination therapy cases, the MERIT report highlights:

1. Concurrent prescribing dates — confirming the physician identified dual pathology
2. Duration of dual therapy — longer combination regimens document persistent, complex injury
3. Dose adjustments — increases in either agent suggest worsening or refractory symptoms
4. Addition of adjunctive medications — gastroprotective agents (omeprazole) prescribed alongside NSAIDs document careful medical management and anticipated long-term NSAID use

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Combination therapy prescribing tells us the injury is more complex than a single-mechanism problem. When we document this in the MERIT report, we are translating clinical prescribing decisions into language that adjusters and defense counsel can understand."

Handling Adjuster Challenges

"Two medications for the same injury is overtreatment." Counter: These medications target entirely different pathological processes. A muscle relaxant cannot reduce inflammation, and an NSAID cannot relieve centrally-mediated spasm. Combination therapy is guideline-concordant care.

"The patient could just take ibuprofen for both." Counter: Over-the-counter ibuprofen does not address the muscle spasm component. Prescribing a dedicated muscle relaxant alongside a prescription NSAID reflects the physician's clinical judgment that the injury warrants targeted dual-mechanism therapy.

"The combination increases side effect risk." Counter: Muscle relaxants and NSAIDs have non-overlapping side effect profiles. Physicians prescribe this combination specifically because it provides additive efficacy without compounding toxicity — unlike, for example, combining two opioids.

[!TIP] If the prescriber added a proton pump inhibitor (omeprazole, pantoprazole) to protect against NSAID-induced GI injury, include this in your demand narrative. It documents that the physician anticipated long-term NSAID use — objective evidence that the injury requires extended treatment.

Pharmacy Lien Access for Combination Therapy

Patients on combination regimens face higher out-of-pocket costs because they are paying for two or more prescriptions simultaneously. A pharmacy lien through LienScripts eliminates this financial barrier, ensuring patients receive their full prescribed regimen without gaps. Treatment gaps — periods where the patient filled the NSAID but not the muscle relaxant due to cost — are exactly the type of inconsistency that defense counsel exploits.

Related Resources

• Cyclobenzaprine After a Rear-End Collision
• Meloxicam for Knee Injury
• Celecoxib vs Ibuprofen for Injury Treatment
• Omeprazole and NSAID Protection
• How LienScripts Works